Vimarsana
Biggest News Aggregation in the World

Page 34 - Merck Sharp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Merck Sharp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Merck Sharp Today - Breaking & Trending Today

Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records - Vimarsana News

Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records

Objectives To assess the effectiveness of live zoster vaccine during more than 10 years after vaccination; and to describe methods for ascertaining vaccine effectiveness in the context of waning. Design Real world cohort study using electronic health records. Setting Kaiser Permanente Northern California, an integrated healthcare delivery system in the US, 1 January 2007 to 31 December 2018. Population More than 1.5 million people aged 50 years and older followed for almost 9.4 million person years. Main outcome measure Vaccine effectiveness in preventing herpes zoster, postherpetic neuralgia,...

Source: bmj.com
Incipient Ulceration May Affect Prognosis in Primary Melanoma - Vimarsana News

Incipient Ulceration May Affect Prognosis in Primary Melanoma

Assigning a lower-risk pathologic T stage to such melanomas may not be appropriate, the study authors conclude.

Kidney Cancer Study Shows Improved Outcomes for Patients With Advanced Disease When Treated With Belzutifan Over Everolimus - Vimarsana News

Kidney Cancer Study Shows Improved Outcomes for Patients With Advanced Disease When Treated With Belzutifan Over Everolimus

Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma, the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.

Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak - Vimarsana News

Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak

Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak

Gilead Sciences Announces Third Quarter 2023 Financial Results - Vimarsana News

Gilead Sciences Announces Third Quarter 2023 Financial Results

07.11.2023 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023. “Gilead has now delivered two years of consistent growth in our base business. In the third quarter, this continued growth was driven by ...